IMF Videos Search Content For Healthcare Professional (132) Healthcare Provider (132) Care Partner (67) Patient (67) Series - Any - ASCO/EHA (51) ASH (69) Ask Dr. Durie (23) Black Swan Research Initiative (2) Emerging Therapies (3) Facebook Live (6) IMWG (4) Living Well with Myeloma (2) Myeloma in a Minute (5) Myeloma Made Simple (5) Myeloma University (4) Patient & Family Webinar (1) Q&A (11) Recent News and Developments (4) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (68) High-Risk Myeloma (45) High-risk Smoldering Myeloma (38) Late Relapse (4–6 Lines of Therapy) (84) MGUS (39) Newly Diagnosed (Pre-Treatment or First Treatment) (63) Smoldering Myeloma (49) Types of Therapy Immunomodulatory drugs (IMiDs) (60) Immunotherapies (CAR T; BiTE, etc.) (100) Monoclonal antibodies (54) Proteasome inhibitors (46) Stem cell transplant (38) Steroids (42) Supportive Care (43) Year Published 2026 (20) 2025 (32) 2024 (52) 2023 (43) 2022 (17) 2021 (12) 2020 (1) 2019 (10) 2018 (2) 2017 (1) 2016 (2) Trusted Voices Dr. Joseph Mikhael (36) Dr. Brian GM Durie (20) Dr. María-Victoria Mateos (7) Dr. Saad Usmani (3) Dr. Shaji Kumar (2) Dr. Sigurður Kristinsson (2) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (1) Donna Catamero, ANP-BC, OCN, CCRC (1) Dr. Sagar Lonial (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) February 15, 2024 ASH Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients with Newly Diagnosed Myeloma in the Determination Trial February 15, 2024 ASH Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial February 15, 2024 ASH Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients January 31, 2024 ASH BCMAxCD3 Bispecific Antibody Elranatamab Is Effective in Patient Myeloma Relapsed after BCMA CAR-T January 25, 2024 ASH Post American Society of Hematology (ASH) Summary January 25, 2024 ASH Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study January 12, 2024 ASH Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3 January 12, 2024 ASH Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand) January 11, 2024 ASH Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose January 11, 2024 ASH Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma January 11, 2024 ASH Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma January 11, 2024 ASH Load More
